{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:46:41Z","timestamp":1789958801726,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2011,5,20]],"date-time":"2011-05-20T00:00:00Z","timestamp":1305849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,5,20]],"date-time":"2011-05-20T00:00:00Z","timestamp":1305849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1038\/leu.2011.116","type":"journal-article","created":{"date-parts":[[2011,5,20]],"date-time":"2011-05-20T05:08:36Z","timestamp":1305868116000},"page":"1433-1438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia"],"prefix":"10.1038","volume":"25","author":[{"given":"M","family":"Pfirrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Lauseker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Sau\u00dfele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Hasford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,20]]},"reference":[{"key":"BFleu2011116_CR1","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/sj.bjc.6601118","volume":"89","author":"TG Clark","year":"2003","unstructured":"Clark TG, Bradburn MJ, Love SB, Altman DG . Survival analysis part I: basic concepts and first analyses. Br J Cancer 2003; 89: 232\u2013238.","journal-title":"Br J Cancer"},{"key":"BFleu2011116_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Amer Statist Assoc 1958; 53: 457\u2013481.","journal-title":"J Amer Statist Assoc"},{"key":"BFleu2011116_CR3","first-page":"365","volume-title":"Practical Statistics for Medical Research","author":"DG Altman","year":"1991","unstructured":"Altman DG . Practical Statistics for Medical Research. Chapman & Hall: London, 1991, pp 365\u2013387."},{"key":"BFleu2011116_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-4899-3115-3","volume-title":"Modelling Survival Data in Medical Research","author":"D Collett","year":"1994","unstructured":"Collett D . Modelling Survival Data in Medical Research. Chapman & Hall: London, 1994, pp 15\u201349."},{"key":"BFleu2011116_CR5","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994\u20131004.","journal-title":"N Engl J Med"},{"key":"BFleu2011116_CR6","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","volume":"29","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, M\u00fcller MC, Pletsch N et al. Tolerability-Adapted Imatinib 800\u2009mg\/d Versus 400\u2009mg\/d Versus 400\u2009mg\/d Plus Interferon-\u03b1 in Newly Diagnosed Chronic Myeloid Leukemia. J Clin Oncol 2011; 29: 1634\u20131642.","journal-title":"J Clin Oncol"},{"key":"BFleu2011116_CR7","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251\u20132259.","journal-title":"N Engl J Med"},{"key":"BFleu2011116_CR8","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260\u20132270.","journal-title":"N Engl J Med"},{"key":"BFleu2011116_CR9","first-page":"1126","volume":"114","author":"M Deininger","year":"2009","unstructured":"Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. ASH Annual Meeting Abstracts 2009; 114: 1126.","journal-title":"ASH Annual Meeting Abstracts"},{"key":"BFleu2011116_CR10","first-page":"167","volume-title":"The Statistical Analysis of Failure Time Data","author":"JD Kalbfleisch","year":"1980","unstructured":"Kalbfleisch JD, Prentice RL . The Statistical Analysis of Failure Time Data. Wiley: New York, 1980, pp 167\u2013171."},{"key":"BFleu2011116_CR11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/b97377","volume-title":"Survival Analysis: Techniques for Censored and Truncated Data","author":"JP Klein","year":"2003","unstructured":"Klein JP, Moeschberger ML . Survival Analysis: Techniques for Censored and Truncated Data, 2nd edn. Springer: New York, 2003, pp 50\u201357."},{"key":"BFleu2011116_CR12","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1002\/sim.2712","volume":"26","author":"H Putter","year":"2007","unstructured":"Putter H, Fiocco M, Geskus RB . Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007; 26: 2389\u20132430.","journal-title":"Stat Med"},{"key":"BFleu2011116_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","volume":"40","author":"L Scrucca","year":"2007","unstructured":"Scrucca L, Santucci A, Aversa F . Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007; 40: 381\u2013387.","journal-title":"Bone Marrow Transplant"},{"key":"BFleu2011116_CR14","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041\u20136051.","journal-title":"J Clin Oncol"},{"key":"BFleu2011116_CR15","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695\u2013706.","journal-title":"Stat Med"},{"key":"BFleu2011116_CR16","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ . A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141\u20131154.","journal-title":"Ann Stat"},{"key":"BFleu2011116_CR17","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/sim.1070","volume":"21","author":"JB Choudhury","year":"2002","unstructured":"Choudhury JB . Non-Parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Stat Med 2002; 21: 1129\u20131144.","journal-title":"Stat Med"},{"key":"BFleu2011116_CR18","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1200\/JCO.2008.20.4107","volume":"27","author":"TR Fleming","year":"2009","unstructured":"Fleming TR, Rothmann MD, Lu HL . Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 2009; 27: 2874\u20132880.","journal-title":"J Clin Oncol"},{"key":"BFleu2011116_CR19","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","volume":"1","author":"JR Anderson","year":"1983","unstructured":"Anderson JR, Cain KC, Gelber RD . Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710\u2013719.","journal-title":"J Clin Oncol"},{"issue":"3","key":"BFleu2011116_CR20","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J. Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment. The EUTOS score. Blood 2011; e-pub ahead of print 2 May 2011; doi:10.1182\/blood-2010-12-319038.","journal-title":"Blood"},{"key":"BFleu2011116_CR21","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809\u20131820.","journal-title":"Blood"},{"key":"BFleu2011116_CR22","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version v403: June 14, 2010. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf."},{"key":"BFleu2011116_CR23","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1200\/JCO.2010.30.2802","volume":"28","author":"LK Mell","year":"2010","unstructured":"Mell LK, Jeong JH . Pitfalls of using composite primary end points in the presence of competing risks. J Clin Oncol 2010; 28: 4297\u20134299.","journal-title":"J Clin Oncol"},{"key":"BFleu2011116_CR24","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"F-X Mahon","year":"2010","unstructured":"Mahon F-X, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029\u20131035.","journal-title":"Lancet Oncol"},{"key":"BFleu2011116_CR25","first-page":"463","volume-title":"Practical Statistics for Medical Research","author":"DG Altman","year":"1991","unstructured":"Altman DG . Practical Statistics for Medical Research. Chapman & Hall: London, 1991, pp 463\u2013464."},{"key":"BFleu2011116_CR26","first-page":"673","volume-title":"Epidemiology: study design and analyis","author":"M Woodward","year":"2005","unstructured":"Woodward M . Epidemiology: study design and analyis. Chapman & Hall\/CRC: Boca Raton, 2005, pp 673\u2013720."},{"key":"BFleu2011116_CR27","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/jnci\/89.21.1616","volume":"89","author":"Chronic Myeloid Leukemia Trialists Collaborative Group","year":"1997","unstructured":"Chronic Myeloid Leukemia Trialists Collaborative Group. Interferon Alfa Versus Chemotherapy for Chronic Myeloid Leukemia: A Meta-analysis of Seven Randomized Trials. J Natl Cancer Inst 1997; 89: 1616\u20131620.","journal-title":"J Natl Cancer Inst"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2011116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011116","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T09:58:17Z","timestamp":1648720697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2011116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,20]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["BFleu2011116"],"URL":"https:\/\/doi.org\/10.1038\/leu.2011.116","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,20]]},"assertion":[{"value":"1 April 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}